Table 5.

Influence of baseline patients' characteristics, MPT treatment and grade 3-4 hematologic and non-hematologic adverse events on progression-free survival and overall survival. Hazard ratios (HR) and 95% confidence interval (95% CI) from Cox frailty models.

Table 5.